361 related articles for article (PubMed ID: 16788320)
21. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis.
Wang YX; da Cunha V; Vincelette J; Zhao L; Nagashima M; Kawai K; Yuan S; Emayan K; Islam I; Hosoya J; Sullivan ME; Dole WP; Morser J; Buckman BO; Vergona R
Thromb Haemost; 2007 Jan; 97(1):54-61. PubMed ID: 17200771
[TBL] [Abstract][Full Text] [Related]
22. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
[TBL] [Abstract][Full Text] [Related]
23. Platelets and endothelial cells act in concert to delay thrombolysis--evidence from an in vitro model of the human occlusive thrombus.
Hantgan RR; Jerome WG; Handt S
Thromb Haemost; 1998 Mar; 79(3):602-8. PubMed ID: 9531049
[TBL] [Abstract][Full Text] [Related]
24. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
Wootton DM; Popel AS; Alevriadou BR
Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013
[TBL] [Abstract][Full Text] [Related]
25. Biochemical and biophysical conditions for blood clot lysis.
Sabovic M; Blinc A
Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642
[TBL] [Abstract][Full Text] [Related]
26. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
Lijnen HR; De Wreede K; Demarsin E; Collen D
Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
[TBL] [Abstract][Full Text] [Related]
27. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
[TBL] [Abstract][Full Text] [Related]
28. The effect of 40 kHz ultrasound on tissue plasminogen activator-induced clot lysis in three in vitro models.
Pieters M; Hekkenberg RT; Barrett-Bergshoeff M; Rijken DC
Ultrasound Med Biol; 2004 Nov; 30(11):1545-52. PubMed ID: 15588966
[TBL] [Abstract][Full Text] [Related]
29. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
[TBL] [Abstract][Full Text] [Related]
30. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI
Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600
[TBL] [Abstract][Full Text] [Related]
31. A reconstituted dilute blood clot lysis assay for the medium throughput screening of thrombolytic compounds.
Gadbut AP; Schullek JR; Hanel AM; MacAllan DR
Anal Biochem; 1999 May; 270(1):24-32. PubMed ID: 10328761
[TBL] [Abstract][Full Text] [Related]
32. [Staphylokinase--a specific plasminogen activator].
Rozpończyk E; Szemraj J; Malinowski M; Rozpończyk J
Postepy Biochem; 2006; 52(1):80-6. PubMed ID: 16869305
[TBL] [Abstract][Full Text] [Related]
33. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.
Korninger C; Collen D
Thromb Haemost; 1981 Aug; 46(2):561-5. PubMed ID: 6795744
[TBL] [Abstract][Full Text] [Related]
34. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles.
Chung TW; Wang SS; Tsai WJ
Biomaterials; 2008 Jan; 29(2):228-37. PubMed ID: 17953984
[TBL] [Abstract][Full Text] [Related]
35. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and Factor XIII.
Nielsen VG; Steenwyk BL; Gurley WQ
J Heart Lung Transplant; 2006 Oct; 25(10):1247-52. PubMed ID: 17045938
[TBL] [Abstract][Full Text] [Related]
36. Sonothrombolysis is effective with recombinant tissue-type plasminogen activator, but not with Abciximab. Results from an in vitro study with whole blood clots and platelet-rich clots.
Eggers J; Ossadnik S; Hütten H; Seidel G
Thromb Haemost; 2009 Dec; 102(6):1274-7. PubMed ID: 19967161
[TBL] [Abstract][Full Text] [Related]
37. Effects of colloid and crystalloid solutions on endogenous activation of fibrinolysis and resistance of polymerized fibrin to recombinant tissue plasminogen activator added ex vivo.
Mittermayr M; Streif W; Haas T; Fries D; Velik-Salchner C; Klingler A; Innerhofer P
Br J Anaesth; 2008 Mar; 100(3):307-14. PubMed ID: 18158312
[TBL] [Abstract][Full Text] [Related]
38. Influence of homocysteine on fibrin network lysis.
Lauricella AM; Quintana I; Castañon M; Sassetti B; Kordich L
Blood Coagul Fibrinolysis; 2006 Apr; 17(3):181-6. PubMed ID: 16575255
[TBL] [Abstract][Full Text] [Related]
39. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
40. Flow through clots determines the rate and pattern of fibrinolysis.
Blinc A; Kennedy SD; Bryant RG; Marder VJ; Francis CW
Thromb Haemost; 1994 Feb; 71(2):230-5. PubMed ID: 8191404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]